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Abstract—The main goal of animal experiments is to test
drug efficacy and toxicity in order to develop new therapies
for infectious and non-infectious diseases as well; however, this
raises ethical issues, and there is an intense debate on the
use of animals in basic biomedical research and preclinical
experiments. This article reviews different animal experiment
techniques along with their advantages and disadvantages, and
discusses the principles for performing more humane animal
research (3Rs: Replacement, Reduction and Refinement). In most
situations, a clinically applicable methodology goes through a
chain of experiments, starting from animal experiments and
ending with human trials.
Index Terms—3Rs; animal models; cancer
I. INTRODUCTION
There is an intense debate on the use of animals in basic
biomedical research and preclinical experiments, not only due
to ethical issues but in connection with clinical predictability
and validity as well. On the one side, there are animal rights
groups and some researchers who are convinced that any
kind of experiments on animals should be stopped since
these experiments are not effective or ”even worse, animal
experiments can mislead researchers or even contribute to
illnesses or deaths by failing to predict the toxic effects of
drugs” [1]. On the other side, there are researchers who do
believe that these animal experiments are necessary to advance
medical and biological knowledge [2].
The main goal of animal experiments is to test drug efficacy
and toxicity in order to develop new therapies for infectious
and non-infectious diseases as well. The most significant
problems regarding the use of animals for research are: i)
ethical issues, ii) the need of skilled animal caretakers and
other trained manpower [3], and finally iii) time and money
consuming protocols [4].
The paper is organized as follows. In Section II, the prin-
ciples for performing more humane animal research, called
as the principles of 3Rs: Reduction, Replacement and Refine-
ment strategies, are discussed. Section III presents alternative
methods to avoid animal experiments, these methods include
computer models, cells and tissue cultures, and alternative
organisms. Section IV describes five basic model groups of
animal models in cancer research, namely ectopic xenograft
models, orthotopic tumor models, transgenic and genetically
engineered mouse models (GEMMs), primary human tumor-
graft model, and carcinogen-promoter induced multi-stage
tumor models. The paper ends with the conclusion in Section
V. This systematic review was carried out using online med-
ical databases like NCBI (National Center for Biotechnology
Information) [5].
II. THE 3RS
In 1959, William Russell and Rex Burch published the book
entitled The Principles of Humane Experimental Technique [6]
in which they laid the foundations of the 3Rs: Replacement,
Reduction and Refinement guiding principles. In this work,
they provided a framework for performing more humane
animal research which is world-widely used nowadays in
scientific research. The UK’s national organization for the 3Rs,
the NC3Rs (National Centre for the Replacement, Refinement
& Reduction of Animals in Research) [7], re-defined these
principles in order to provide contemporary scientific stan-
dards [8]. Fig. 1 summarizes the principles of 3Rs.
A. Reduction
The object of reduction strategies is to minimize the number
of animals used per experiment. Reduction methods include
i) sequential animal testing, ii) integrated testing and deci-
sion strategies (ITDSs), iii) appropriate statistical design and
analysis, iv) data and resources sharing between research
groups, and v) experiment project coordination by responsive
management.
The main idea of sequential testing [9] is a statistical
approach to significantly decrease the number of animals used
in acute oral toxicity testing. Based on the response of the first
animal to a toxicity test (e.g. ’mild’, ’moderate’, or ’severe’),
further animals will be involved accordingly to the experiment,
ensuring a sequential scheme in contrast to parallel testing
which requires much more animals. The obvious drawback of
this method is the longer time requirement.
ITDSs are information-based decision strategies [9] which
collect every available data and information from multiple
sources in order to make step-by-step hazard classification
decisions.
Appropriately designed experiments are the key for reliable
results [10], [11]. Statistical design includes randomization (in
order to handle known or unknown variation), blinding (to
avoid bias), pilot studies (to test the logistics of the study),
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1. Full replacement 
• avoids the use of any research animals
a) human volunteers
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c) mathematical and computer models
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2. Partial replacement 
• replaces the use of animals
a) animals that are not considered capable of 
experiencing suffering (e.g. Drosophila)
b) primary cells (and tissues) taken from animals 
killed solely for this purpose
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reproducible
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is maximized
a) longitudinal measurements in the same 
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3. Sharing data and resources between research 
groups 
Refinement
1. minimize animal pain, suffering, distress
a) appropriate anesthesia and analgesia
b) training animals to cooperate with 
procedures
2. improve animal welfare
a) allows the expression of species-specific 
behaviors 
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Fig. 1. The principles of 3Rs based on NC3Rs [7].
choice of dependent and independent variables, power anal-
ysis (to determine the sample size), and evaluative statistical
analysis (tests).
Existing resources, namely the data that have been collected
from years of animal experiments should be shared between
research groups in order to minimize the use of animal testing
[12]. This can be achieved by e.g. cross-departmental projects
coordinated by responsive management [13].
B. Replacement
Replacement methods aim to avoid the use of any research
animals or to replace the use of animals. Replacement methods
can be grouped based on the type of animals which are used
[7]. In this sense, we can talk about full replacement which
totally avoids the use of animals; on the other hand, partial
replacement aims to use animals which are less likely or not
capable of experiencing suffering (typically invertebrates like
Drosophila melanogaster and immature forms of vertebrates).
The other possible grouping of replacement methods is based
on whether the animals suffer during the experiment or not
[4]. In the case of relative replacement, animals are used in
the experiment but not exposed to any suffering or distress;
while absolute replacement means that no animals are used at
all. Note that full replacement and absolute replacement have
the same meaning.
Before carrying out an animal experiment, the literature
should be carefully reviewed in order to collect every relevant
data in the given field. General review articles aim to summa-
rize the corresponding literature and may suggest some novel
idea. Systematic reviews (SRs) are more comprehensive than
general reviews, and provide an opinion on the findings [14].
Meta-analyses (MAs) are quantitative systematic reviews, i.e.
an MA is a mathematical synthesis on primary studies with
the same hypothesis [14]. Evaluating the different literature
sources of experimental evidence on a qualitative basis results
in critical reviews (CRs) [15]. Therefore, animal experiments
can potentially be replaced based on the findings of SRs, MAs
and CRs.
C. Refinement
The purpose of refinement methods is to minimize animal
suffering and improve welfare. Laboratory animals are ex-
posed to two different types of pain and distress. ’Contingent
inhumanity’ occurs as a result of housing animals, while
’direct inhumanity’ is a direct result of research procedures
[16].
The most important refinement strategies are [9] i) the usage
of earlier and more humane endpoints in order to minimize
the distress experienced by an animal [17], ii) applying pain-
relieving anesthetics and analgesics medications, and iii) pro-
viding appropriate veterinary clinical care including frequent
observation and adequate interventions.
Another possible refinement method is the enrichment of
the cage environment which was found to be useful in stress
reduction [4]. It is important to highlight that as a result
of refinement strategies, not only the quality of life of the
laboratory animals but the quality of research and its impact
will be improved – this is also known as ”good welfare equals
good science” [8].
However, conflicts have also been identified between the
”R” principles like reducing overall number of animals versus
minimizing pain and distress for individual animals [18];
”by employing the 3Rs when continuing to use animals for
scientific research, the scientific community can affirm its
moral conscience as well as uphold its obligation to humanity
to further the advancement of science for civilization and
humanity” [2]. Besides this, each researchers individual re-
sponsibility is decisive in the implementation of the 3Rs [3].
III. ALTERNATIVE METHODS
There are numerous alternative methods to avoid / replace
the use of animals in experiments [4], [9], [19]. These methods
have important advantages like time efficiency, better cost
effectiveness, and less man power required; however, they have
limitations as well.
A. Computer models
Computer models are widely used to simulate biological
processes and to carry out in silico simulations. These in silico
simulations are the first step of new medicine design; only
some of the investigated molecules are used for further in
vitro and in vivo experimentation.
Another usage of computer models is to create mathemat-
ical models of physiological processes which allows closed-
loop control design. In cancer therapy, closed-loop control is
conceivable in the following way. A sensor measures tumor
volume or other tumor-associated property which can describe
the progression of the tumor; a controller module runs an
algorithm that calculates the optimal drug administration; and
an anti-cancer drug injector pump closes the loop. Controller
managed automatic therapies have the possibility to be more
cost-effective, to have limited side-effects, and to ensure more
personalized treatment than the current medical protocols [20],
[21].
B. Cells and tissue cultures
Cells and tissue cultures ensure in vitro environment and
hence these methods are the second step to test drug toxicity
and efficacy. These techniques are less expensive and less time
consuming than in vivo experiments, and evidently do not use
live animals. On the other hand, the usability and predictive
value of the acquired results are limited.
C. Alternative organisms
In vivo experiments are the third level of research. In
order to apply replacement methods in in vivo experiments,
alternative organisms can be used (partial replacement). There
are three commonly used alternative organism groups [4]: i)
lower vertebrates, ii) invertebrates, and iii) microorganisms.
Advantages of the use of lower vertebrates are genetic
similarity to the higher vertebrates, and less sensitive ethical
issues. Due to the transparent body, short life cycle and whole
genome sequence availability of Danio rerio (zebra fish), it is a
widely used lower vertebrate, mainly in toxicological studies.
Invertebrates have obvious advantages like small size, short
life cycle, extremely low cost of housing and simple anatomy;
however, regarding the lack of adaptive immune system, there
are limitations in the use of human diseases. The complete
genome sequence of Drosophila melanogaster is available,
and it has four life cycle stages (embryo, larva, pupa and
adult) which makes it a multiple model organism. Another
typically used invertebrate is Caenorhabditis elegans which is
a transparent nematode. It is used as a model for neurological
disorders, diabetes and cancer.
Microorganisms are rapidly growing in liquid or solid
culture, and their genetic system is well defined. Saccha-
romyces cerevisiae is a brewing yeast and an ideal eukaryotic
microorganism for cancer research, especially to study cell
death regulators and programmed cell death.
IV. ANIMAL MODELS IN CANCER RESEARCH
There are five basic model groups of animal models in
cancer research: i) ectopic xenograft models, ii) orthotopic tu-
mor models, iii) transgenic and genetically engineered mouse
models (GEMMs), iv) primary human tumorgraft model, and
v) carcinogen-promoter induced multi-stage tumor models
[22].
The genetic and epigenetic complexity and diversity of
tumors, all together with intra- and inter-tumor heterogeneity
results phenotypic and genotypic heterogeneity [22]. An ideal
animal model, which is able to model this complexity and
diversity, has the following properties [23]: i) similarity in
genetic basis (to human system), ii) anatomical and physio-
logical similarity, iii) similarity in pathological mechanisms,
iv) phenotypic endpoints similar to the corresponding clinical
studies, v) responsive to known drugs with clinical efficacy,
and vi) predictive in terms of clinical predictability.
A. Ectopic xenograft models
Implantation of tumor cell lines can be done subcutaneously
(sc), intraperitoneally (ip), intravenously (iv), or intramuscu-
larly (im) into immunocompetent or immuno-deficient rodents,
typically into a non-physiologic growth location. Using ectopic
xenograft models [24], anti-tumor efficacy, tumor pharmacody-
namic/pharmacokinetic (PD/PK) relationships can be investi-
gated. The main advantages are the possibility of cost and time
effective tumor measurements, and easy reproducibility of the
experiments; while the most important disadvantages of these
models are the loss of inter- and intra-tumor heterogeneity, and
the lack of native tumor microenvironment. As a consequence,
the clinical predictability is limited.
B. Orthotopic tumor models
In the case of orthotopic tumor models [17], [22], the
implantation is carried out into organ of origin, and hence
local and metastatic spread can occur. Immunocompetent and
immuno-deficient rodents can be used as well. These models
enable the examination of primary tumor growth in correct
microenvironment, the effects on both local and metastatic
tumor spread, and survival endpoints. Strengths of these mod-
els are the presence of proper tumor microenvironment, and
the observability of tumor-stromal interactions and metastases.
Artificially selected cell lines which are histologically dis-
similar from human tumors is one of the weaknesses of the
model, as well as the difficult in situ examination of tumor
development. Orthotopic tumor models have limited–moderate
clinical predictability.
C. Transgenic and genetically engineered mouse models
(GEMMs)
In transgenic models, the hosts are immunocompetent mice
ensuring appropriate microenvironment for spontaneous in situ
tumor development. These models allow to examine immune
system response and surveillance; in addition, metastatic and
invasive ability of the tumor, and tumorous angiogenesis can
be investigated as well [23]. Due to genetic, histological and
phenotypic similarities to primary tumors, these are well-used
models to human cancers; however, the lack of tissue-specific
promoters and differences in metastatic patterns compared to
human tumors are limitations of these models. GEMMs and
transgenic models are predictive models in terms of clinical
predictability.
D. Primary human tumorgraft models
In primary human tumorgraft models / personalized tu-
morgrafts, primary human tumors are freshly excised and
propagated or directly implanted into immunedeficient mice.
Due to the fact that there is no in vitro selection of tumor
cells, genetic heterogeneity of the original tumor is retained,
thus the effects of new chemical entities (NCEs) can be
evaluated ectopically or orthotopically. These methods have
several advantages like phenotypic, histological and genetic
stabilization of the primary tumor; in addition, primary human
tumorgraft models maintain stem cell and stromal elements
and the ability of the tumor to metastasize. High cost of the
experiment and limited access to freshly excised human tumor
cells are difficulties of these models, nevertheless personalized
tumorgrafts have high clinical predictability.
E. Carcinogen-promoter induced multi-stage tumor models
Administration of polycyclic aromatic hydrocarbon (PAH)
carcinogenic agents into immunocompetent rodents results in
time-dependent and multi-stage progression models. These
models allow the examination of the effect of different
chemotherapeutic agents for preventive and interventional
purposes. Since carcinogen-promoter induced models show
biochemical similarities to human tumors, stage-specific de-
velopment is similar as well, hence the effect of immune
surveillance on tumor cells can be studied. These models have
drawbacks like the diverse genetic backgrounds and distinct
sensitivity to PAH carcinogenic agents of the mice, and the
high cost of the experiments; however, carcinogen-promoter
induced models have clinical predictability regarding tumor
development.
The poor concordance between animal experiments and
clinical trials can be explained not only with physiological
differences between the species, but some other factors like
i) poor quality animal experiments (partially due to the lack
of best-practice standards for animal testing [19]), ii) random
error, and iii) publication bias [25]. Publication bias means that
the outcome of an experiment influences the decision whether
to publish or not; studies with significant results are more
likely to be published than ’null result’ research.
V. CONCLUSION
As it was shown, every animal model has its own limita-
tions; however, appropriately selected models and prudently
conducted experiments can have valid clinical predictability.
For instance, the results of a meta-analysis in rodent models of
colon carcinogenesis suggest that rodent models are good pre-
dictors of humans effects, but the prediction is not accurate for
all investigated agents [26]. Thus animal research results have
to be systematically and/or critically reviewed for evidence of
safety and efficacy.
Despite the intense debate on the use of animals in biomedi-
cal research, it is a fact that almost every form of conventional
medical treatment (including drug and vaccine development,
and surgical therapy) was developed with the help of animal
research [15]. In addition, although animal cancer models have
important role in cancer research due to their physiological
relevance, in the final safety and efficacy investigations, human
volunteers and patients are unavoidable [22]. To sum up,
cancer research is a complex chain of in silico, in vitro, in
vivo animal and in vivo human experiments. These chain-links
are closely linked together, and if only one chain-link is taken
off from that closed structure, the whole system may collapse
resulting in the lack of ability to help people survive cancer
[27].
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